BREXPIPRAZOLE by Novartis is 12. First approved in 2022.
Drug data last refreshed 22h ago
12.1 Mechanism of Action The mechanism of action of REXULTI in the adjunctive treatment of major depressive disorder, treatment of agitation associated with dementia due to Alzheimer's disease, or treatment of schizophrenia is unknown. However, the efficacy of REXULTI may be mediated through a…
Worked on BREXPIPRAZOLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia